COPD - clinical and epidemiological aspects

Thematic Poster Session
Chairs: G. Viegi (Pisa, Italy), M. Kogevinas (Barcelona, Spain)

Validation of the Yale physical activity survey in COPD patients D. Donaire-Gonzalez, I. Serra, J. M. Antó, J. Roca, E. Balcells, E. Rodriguez, E. Farrero, J. Garcia-Aymerich (Barcelona, Spain)
An increase of 1%-predicted in FEV₁ considerably saves costs for COPD S. A. Jansson, J. Rocklöv, A. Lindberg, B. Forsberg, J. Björkman, E. Rönmark, B. Lundbäck (Stockholm, Umeå, Luleå, Gothenburg, Sweden)
The impact of body composition on walking distance in the six-minute walk test in COPD patients M. Waatevik, P. Bakke, J. Hardie, T. M. Eagan (Bergen, Norway)
COPD medications and risk of pneumonia in the UK D. Miller, H. Muellerova, T. Sampson, R. Baxter, K. Davis (Research Triangle Park, United States Of America; Greenford, United Kingdom)
Increase in plasma alpha-linolenic acid is positively associated with lung function. The emphysema and cancer action program (EMCAP) study S. Mesia-Vela, J. H. M. Austin, H. Campos, D. Yankelevitz, F. Ahmed, R. G. Barr (New York, NY, Boston, MA, Ithaca, NY, United States Of America)
Chronic obstructive pulmonary disease in waterpipe smokers; a population-based controlled study M. Bahtouee, F. Azizi, N. Motamed, F. Nekouee (Bushehr Port, Bushehr Province, Islamic Republic Of Iran)
Risk of bias in COPD trials B. Bausch, A. Spaar, J. Kleijnen, M. Puhan (Zurich, Switzerland; York, United Kingdom)
Gender impact on associations between socioeconomic status and lung function decline in a general population A. Johannessen, T. Eagan, E. Omenaas, A. Gulsvik (Bergen, Norway)
Genetic influence on chronic mucus hypersecretion – a twin study T. Ingebrigtsen, S. F. Thomsen, K. O. Kyvik, E. K. Silverman, J. Vestbo, V. Backer (Copenhagen, Odense, Denmark; Boston, United States Of America)
Preselection of patients at high risk for COPD by simple screening questions H. Koegler, N. Metzdorf, T. Welte, T. Glaab (Ingelheim, Hannover, Germany)
COPD treatment in primary care in ²living with COPD² study P. De Lucas, J. M. Rodriguez Gonzalez-Moro, J. L. Izquierdo, E. Anton, A. Martin (Madrid, Guadalajara, Alcobendas, Spain)
FEV₁/Height² could be a better alternative than FEV₁ in predicting all cause mortality in patients with COPD S. Schembri, S. Morant, T. MacDonald, J. Winter, J. Winter (Dundee, United Kingdom)
Use of the multidimensional index BOD to characterise the natural history of COPD N. Keaney, A. Kay, K. Ansari, M. Shamssain, T. Hildreth, I. Taylor (Sunderland, United Kingdom)
High prevalence of vertebral deformities in COPD patients is not related only to systemic steroid use A. Kjensli, M. S. Ryg, J. A. Falch, I. Ellingsen (Hakadal, Oslo, Norway)
Four years follow-up of exacerbations in a cohort of COPD patients: 1 year interim results (EXACO study) I. Tillie Leblond, F. Masure, G. Birraux, I. Boucot, F. Deschamps, A. Myftiu, J. Ostinelli, C. Pribil, C. Philippe (Lille, Reims, Paris, Marly Le Roi, Rueil Malmaison, France)
Exacerbations in a cohort of COPD patients: frequent exacerbators characteristics after 1-year follow-up (EXACO study – interim analysis) I. Tillie Leblond, F. Masure, G. Birraux, I. Boucot, F. Deschamps, A. Myftiu, J. Ostinelli, C. Pribil, C. Philippe (Lille, Reims, Paris, Marly Le Roi, Rueil Malmaison, France)
The OLIN-studies COPD-cohort, 3-year mortality A. Lindberg, L. G. Larsson, A. C. Jonsson, S. Sundberg, E. Rönmark, B. Lundbäck (Luleå, Umeå, Gothenburg, Sweden)
Prevalence, correlates and mortality impact of chronic obstructive pulmonary disease in end stage kidney disease B. D. Kent, E. Eltayeb, A. G. Stack (Co. Donegal, Ireland)
Predictors of mortality in COPD M. Puhan, P. Dietrich, G. Ter Riet (Zurich, Switzerland)
A prospective study on vascular reactivity of the brachial artery in patients with stable COPD L. Cekici, A. Valipour, P. Eickhoff, K. Geyer, O. C. Burghuber (Vienna, Austria)